Polyarteritis nodosa and extrahepatic manifestations of HBV infection: Thecase against autoimmune intervention in pathogenesis

Citation
C. Trepo et L. Guillevin, Polyarteritis nodosa and extrahepatic manifestations of HBV infection: Thecase against autoimmune intervention in pathogenesis, J AUTOIMMUN, 16(3), 2001, pp. 269-274
Citations number
27
Categorie Soggetti
Immunology
Journal title
JOURNAL OF AUTOIMMUNITY
ISSN journal
08968411 → ACNP
Volume
16
Issue
3
Year of publication
2001
Pages
269 - 274
Database
ISI
SICI code
0896-8411(200105)16:3<269:PNAEMO>2.0.ZU;2-E
Abstract
Numerous extrahepatic manifestations have been reported in patients with bo th acute and chronic hepatitis B (arthralgias or arthritis, skin rashes, gl omerulonephritis and neuritis), all of which are present in polyarteritis n odosa (PAN) which is the most unique and spectacular extrahepatic manifesta tion. In the 1970s, the frequency of PAN due to the hepatitis B (HBV) reach ed 30%. Immunization programs explain the decrease and it is now down to 7% . PAN usually occurs within 6 months of infection. Clinical manifestations reflect this most classic form of PAN, Hepatic manifestations including, AL T/AST elevations are mild and usually overlooked. Besides HBV, other viruse s may be responsible for cases of vasculitides including PAN, HIV, Parvovir us B19, and EBV. Different pathogenic mechanisms have been identified but i mmune complexes are mainly thought to be responsible. in glomerulonephritis , detailed immunostaining and ultrastructural findings indicate that HBe an tigen (Ag) is more likely to be the responsible antigen. In PAN, fewer repo rts are available and early studies with poorly defined antibodies need to be revisited. Interestingly almost all cases of HBV/PAN are associated with wild-type HBV infection, characterised by HBe antigenemia and high HBV rep lication, supporting the concept that lesions could result from the deposit of viral Ag/Ab complexes soluble in Ag excess, possibly involving HBe Ag. The recent observation of PAN cases associated with precore mutation which abrogates the formation of HBe Ag challenges this view. It may suggest that other, still undefined, circulating HBV-related Ag(s) distinct from HBe Ag could be involved. Remarkably, none of the HBV/PAN cases or glomerulonephr itis exhibit antineutrophil cycoplasmic antibodies (ANCA) reactivity. Viral PAN can now be completely separated from other form of vasculitis mostly a utoimmune in nature. Based on the efficacy of antiviral agents in chronic h epatitis B and of plasma exchanges in PAN we combined both therapies to tre at HBV PAN. This was associated with swift recovery, even in the most sever e forms. The perfect time correlation between inhibition of virus replicati on and resolution of all bioclinical signs suggest a direct pathogenic role of the virus possibly via immune complexes. Traditional immunosuppressive and steroid therapy should no longer be used for HBV PAN cases. (C) 2001 Ac ademic Press.